Johnson & Johnson will cut COVID-19 vaccine shipments by 86% in the coming week, according to CDC projections. The week of April 5, the company shipped nearly 5 million doses. Next week, that figure could fall to approximately 700,000. The company anticipates that it can eventually deliver up to 8 million doses weekly, assuming FDA authorizes…
Emergent reportedly had serious problems at Baltimore vaccine plant
Emergent BioSolutions was not prepared to take on the mammoth task of churning out millions of COVID-19 vaccine doses to support U.S. efforts to end the pandemic, according to a report published today in The New York Times. Emergent was ill-equipped despite a $163 million federal contract to prepare the facility for high-volume production, according…
Feds put J&J in charge of vaccine production at Emergent plant
Johnson & Johnson (NYSE:JNJ) announced that it assumed full responsibility for the production of its COVID-19 vaccine at the Emergent BioSolutions Bayview (Baltimore) facility. The company’s announcement comes days after news broke that a factory error made at that facility resulted in 15 million discarded COVID-19 vaccines. New Brunswick, N.J.–based J&J’s single-dose vaccine was authorized…
Factory error ruins 15M J&J COVID-19 vaccine doses
Employees at an Emergent BioSolutions (NYSE:EBS) facility in Baltimore made a mistake several weeks ago when formulating the ingredients for Johnson & Johnson’s COVID-19 vaccine, requiring 15 million doses of it to be discarded. A quality control process revealed that one batch of a drug substance for the J&J COVID-19 vaccine “did not meet quality…
Amid controversy, Biden cancels Emergent Biosolutions visit
The White House scrapped plans to hold a meeting today at a Baltimore-based vaccine plant run by Emergent BioSolutions following an exposé from The New York Times. The Biden administration also announced plans to conduct an audit of the Strategic National Stockpile after the publication of the article, which described how the biopharmaceutical company lobbied…
J&J to pay Emergent BioSolutions an initial $480m to make COVID-19 vaccine
Emergent BioSolutions announced a five-year manufacturing agreement with Johnson & Johnson’s (NYSE:JNJ) Janssen Pharmaceuticals for the parent company’s SARS-CoV-2 vaccine candidate. Gaithersburg, Md.-based Emergent is set to provide contract development and manufacturing services to produce Johnson & Johnson’s Ad26.COV2-S vaccine candidate at scale over five years, with the deal valued at approximately $480 million for…
How Johnson & Johnson is expanding manufacturing for a potential coronavirus vaccine
Johnson & Johnson (NYSE:JNJ) recently announced that its Janssen Pharmaceutical Cos. will collaborate with Emergent BioSolutions to support the manufacturing of its lead investigational COVID-19 vaccine candidate. The New Brunswick, N.J.–based pharmaceutical and medical device giant described the deal as the first in a series of contract manufacturing agreements that it expects to ink as…